6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
section	NN	section	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
:	:	:	:	:	N	O

Retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
and	CC	and	and	and	N	O
potential	JJ	potential	potential	potenti	N	B-Factor
vision	NN	vision	vision	vision	N	B-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

Skin	NNP	skin	skin	skin	N	B-AdverseReaction
discoloration	NN	discoloration	discoloration	discolor	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Neuropsychiatric	NNP	neuropsychiatric	neuropsychiatric	neuropsychiatr	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

QT	NNP	qt	qt	qt	N	B-AdverseReaction
interval	JJ	interval	interval	interv	N	I-AdverseReaction
effect	NN	effect	effect	effect	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O

Suicidal	NNP	suicidal	suicidal	suicid	N	B-AdverseReaction
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
and	CC	and	and	and	N	O
ideation	NN	ideation	ideation	ideat	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)]	NN	)]	)]	)]	N	O

Withdrawal	NNP	withdrawal	withdrawal	withdraw	N	B-AdverseReaction
seizures	VBZ	seizures	seizure	seizur	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)]	NN	)]	)]	)]	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
4%	CD	4%	4%	4%	N	O
and	CC	and	and	and	N	O
twice	RB	twice	twice	twice	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
dizziness	JJ	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
confusional	JJ	confusional	confusional	confusion	N	B-AdverseReaction
state	NN	state	state	state	N	I-AdverseReaction
,	,	,	,	,	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
,	,	,	,	,	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
,	,	,	,	,	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
coordination	NN	coordination	coordination	coordin	N	I-AdverseReaction
,	,	,	,	,	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
disturbance	NN	disturbance	disturbance	disturb	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
attention	NN	attention	attention	attent	N	I-AdverseReaction
,	,	,	,	,	N	O
memory	NN	memory	memory	memori	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
gait	NN	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
,	,	,	,	,	N	O
aphasia	NN	aphasia	aphasia	aphasia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysarthria	NN	dysarthria	dysarthria	dysarthria	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
balance	NN	balance	balance	balanc	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
GlaxoSmithKline	NNP	glaxosmithkline	glaxosmithkline	glaxosmithklin	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
825	CD	825	825	825	N	O
-	:	-	-	-	N	O
5249	CD	5249	5249	5249	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

POTIGA	NNP	potiga	potiga	potiga	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
as	IN	as	a	as	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
therapy	NN	therapy	therapy	therapi	N	O
to	TO	to	to	to	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
365	CD	365	365	365	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
premarketing	NN	premarketing	premarketing	premarket	N	O
development	NN	development	development	develop	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
801	CD	801	801	801	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
585	CD	585	585	585	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
1	CD	1	1	1	N	O
year	NN	year	year	year	N	O
or	CC	or	or	or	N	O
longer	JJR	longer	longer	longer	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
311	CD	311	311	311	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Leading	NNP	leading	leading	lead	N	O
to	TO	to	to	to	N	O
Discontinuation	NNP	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
All	NNP	all	all	all	N	O
Controlled	NNP	controlled	controlled	control	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
199	CD	199	199	199	N	O
of	IN	of	of	of	N	O
813	CD	813	813	813	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
and	CC	and	and	and	N	O
45	CD	45	45	45	N	O
of	IN	of	of	of	N	O
427	CD	427	427	427	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
withdrawal	VB	withdrawal	withdrawal	withdraw	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
were	VBD	were	were	were	N	O
dizziness	JJ	dizziness	dizziness	dizzi	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
confusional	JJ	confusional	confusional	confusion	N	B-AdverseReaction
state	NN	state	state	state	N	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Common	JJ	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
All	NNP	all	all	all	N	O
Controlled	NNP	controlled	controlled	control	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O

Overall	JJ	overall	overall	overal	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
and	CC	and	and	and	N	O
occurring	VBG	occurring	occurring	occur	N	O
approximately	RB	approximately	approximately	approxim	N	O
twice	RB	twice	twice	twice	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
rate	NN	rate	rate	rate	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
dizziness	JJ	dizziness	dizziness	dizzi	Y	B-AdverseReaction
(	(	(	(	(	N	O
23%	CD	23%	23%	23%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
(	(	(	(	(	N	O
22%	CD	22%	22%	22%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
confusional	JJ	confusional	confusional	confusion	N	B-AdverseReaction
state	NN	state	state	state	N	I-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
vertigo	FW	vertigo	vertigo	vertigo	Y	B-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
coordination	NN	coordination	coordination	coordin	N	I-AdverseReaction
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
disturbance	NN	disturbance	disturbance	disturb	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
attention	NN	attention	attention	attent	N	I-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
memory	JJ	memory	memory	memori	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
asthenia	RB	asthenia	asthenia	asthenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
gait	JJ	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
aphasia	NN	aphasia	aphasia	aphasia	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
dysarthria	NN	dysarthria	dysarthria	dysarthria	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
balance	NN	balance	balance	balanc	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
most	JJS	most	most	most	N	O
cases	NNS	cases	case	case	N	O
the	DT	the	the	the	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
of	IN	of	of	of	N	O
mild	NN	mild	mild	mild	N	O
or	CC	or	or	or	N	O
moderate	JJ	moderate	moderate	moder	N	O
intensity	NN	intensity	intensity	intens	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Incidence	NNP	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
Trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Adult	NNP	adult	adult	adult	N	O
Patients	NNPS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Partial	NNP	partial	partial	partial	N	O
-	:	-	-	-	N	O
Onset	NN	onset	onset	onset	N	O
Seizures	NNP	seizures	seizure	seizur	Y	O
(	(	(	(	(	N	O
Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
numerically	RB	numerically	numerically	numer	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O
)	)	)	)	)	N	O

Body	NN	body	body	bodi	N	O
System	NNP	system	system	system	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O

600	CD	600	600	600	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
900	CD	900	900	900	N	O
mg	NN	mg	mg	mg	N	O
day	NN	day	day	day	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NNS	mg	mg	mg	N	O
day	NN	day	day	day	N	O
All	DT	all	all	all	N	O

(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
427	CD	427	427	427	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
n	$	n	n	n	N	O
281	CD	281	281	281	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
n	$	n	n	n	N	O
273	CD	273	273	273	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
n	$	n	n	n	N	O
259	CD	259	259	259	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
813	CD	813	813	813	N	O
)	)	)	)	)	N	O

Eye	NN	eye	eye	eye	N	O

Diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction

2	CD	2	2	2	N	O

8	CD	8	8	8	N	O
6	CD	6	6	6	N	O
7	CD	7	7	7	N	O
7	CD	7	7	7	N	O

Blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction

2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O
10	CD	10	10	10	N	O
5	CD	5	5	5	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction

5	CD	5	5	5	N	O

6	CD	6	6	6	N	O
6	CD	6	6	6	N	O
9	CD	9	9	9	N	O
7	CD	7	7	7	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction

1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O
3	CD	3	3	3	N	O

Dyspepsia	NN	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction

2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

General	NNP	general	general	gener	N	O

Fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction

6	CD	6	6	6	N	O

16	CD	16	16	16	N	O
15	CD	15	15	15	N	O
13	CD	13	13	13	N	O
15	CD	15	15	15	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction

2	CD	2	2	2	N	O
4	CD	4	4	4	N	O
6	CD	6	6	6	N	O
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction

2	CD	2	2	2	N	O

4	CD	4	4	4	N	O
1	CD	1	1	1	N	O
5	CD	5	5	5	N	O
3	CD	3	3	3	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NN	weight	weight	weight	Y	B-AdverseReaction

increased	VBN	increased	increased	increas	N	I-AdverseReaction

1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
3	CD	3	3	3	N	O
3	CD	3	3	3	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction

9	CD	9	9	9	N	O

15	CD	15	15	15	N	O
23	CD	23	23	23	N	O
32	CD	32	32	32	N	O
23	CD	23	23	23	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction

12	CD	12	12	12	N	O
15	CD	15	15	15	N	O
25	CD	25	25	25	N	O
27	CD	27	27	27	N	O
22	CD	22	22	22	N	O

Memory	NN	memory	memory	memori	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction

3	CD	3	3	3	N	O
3	CD	3	3	3	N	O
6	CD	6	6	6	N	O
9	CD	9	9	9	N	O
6	CD	6	6	6	N	O

Tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction

3	CD	3	3	3	N	O
3	CD	3	3	3	N	O
10	CD	10	10	10	N	O
12	CD	12	12	12	N	O
8	CD	8	8	8	N	O

Vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction

2	CD	2	2	2	N	O
8	CD	8	8	8	N	O
8	CD	8	8	8	N	O
9	CD	9	9	9	N	O
8	CD	8	8	8	N	O

Abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
coordination	NN	coordination	coordination	coordin	N	I-AdverseReaction

3	CD	3	3	3	N	O
5	CD	5	5	5	N	O
5	CD	5	5	5	N	O
12	CD	12	12	12	N	O
7	CD	7	7	7	N	O

Disturbance	NN	disturbance	disturbance	disturb	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
attention	NN	attention	attention	attent	N	I-AdverseReaction

1	CD	1	1	1	N	O
6	CD	6	6	6	N	O
6	CD	6	6	6	N	O
7	CD	7	7	7	N	O
6	CD	6	6	6	N	O

Gait	NNP	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction

1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
5	CD	5	5	5	N	O
6	CD	6	6	6	N	O
4	CD	4	4	4	N	O

Aphasia	NN	aphasia	aphasia	aphasia	Y	B-AdverseReaction

1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
7	CD	7	7	7	N	O
4	CD	4	4	4	N	O

Dysarthria	NNS	dysarthria	dysarthria	dysarthria	Y	B-AdverseReaction

1	CD	1	1	1	N	O
4	CD	4	4	4	N	O
2	CD	2	2	2	N	O
8	CD	8	8	8	N	O
4	CD	4	4	4	N	O

Balance	NN	balance	balance	balanc	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction

1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
3	CD	3	3	3	N	O
5	CD	5	5	5	N	O
4	CD	4	4	4	N	O

Paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction

2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O
5	CD	5	5	5	N	O
3	CD	3	3	3	N	O

Amnesia	NN	amnesia	amnesia	amnesia	Y	B-AdverseReaction

1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Dysphasia	NN	dysphasia	dysphasia	dysphasia	Y	B-AdverseReaction

1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O

Confusional	JJ	confusional	confusional	confusion	N	B-AdverseReaction

state	NN	state	state	state	N	I-AdverseReaction

3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
8	CD	8	8	8	N	O
16	CD	16	16	16	N	O
9	CD	9	9	9	N	O

Anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction

2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O
5	CD	5	5	5	N	O
3	CD	3	3	3	N	O

Disorientation	NN	disorientation	disorientation	disorient	Y	B-AdverseReaction

1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
5	CD	5	5	5	N	O
2	CD	2	2	2	N	O

Psychotic	JJ	psychotic	psychotic	psychot	Y	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction

0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	O

Dysuria	NNS	dysuria	dysuria	dysuria	Y	B-AdverseReaction

1	CD	1	1	1	N	O

1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O
2	CD	2	2	2	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
hesitation	NN	hesitation	hesitation	hesit	N	I-AdverseReaction

1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O
2	CD	2	2	2	N	O

Hematuria	NNS	hematuria	hematuria	hematuria	Y	B-AdverseReaction

1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O

Chromaturia	NNS	chromaturia	chromaturia	chromaturia	Y	B-AdverseReaction

1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Other	JJ	other	other	other	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
3	CD	3	3	3	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
and	CC	and	and	and	N	O
numerically	RB	numerically	numerically	numer	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
were	VBD	were	were	were	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
hallucinations	NNS	hallucinations	hallucination	hallucin	Y	B-AdverseReaction
,	,	,	,	,	N	O
myoclonus	NN	myoclonus	myoclonus	myoclonu	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
hypokinesia	NN	hypokinesia	hypokinesia	hypokinesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperhydrosis	NN	hyperhydrosis	hyperhydrosis	hyperhydrosi	N	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
,	,	,	,	,	N	O
malaise	NN	malaise	malaise	malais	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
liver	RB	liver	liver	liver	N	I-AdverseReaction
enzymes	RB	enzymes	enzyme	enzym	N	I-AdverseReaction
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O

of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
appear	VBP	appear	appear	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
dose	RB	dose	dose	dose	N	O
related	VBN	related	related	relat	N	O
(	(	(	(	(	N	O
especially	RB	especially	especially	especi	N	O
those	DT	those	those	those	N	O
classified	VBN	classified	classified	classifi	N	O
as	IN	as	a	as	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
and	CC	and	and	and	N	O
nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
confusional	JJ	confusional	confusional	confusion	N	B-AdverseReaction
state	NN	state	state	state	N	I-AdverseReaction
,	,	,	,	,	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
,	,	,	,	,	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
coordination	NN	coordination	coordination	coordin	N	I-AdverseReaction
,	,	,	,	,	N	O
memory	NN	memory	memory	memori	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
gait	NN	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
,	,	,	,	,	N	O
aphasia	NN	aphasia	aphasia	aphasia	Y	B-AdverseReaction
,	,	,	,	,	N	O
balance	NN	balance	balance	balanc	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysuria	NN	dysuria	dysuria	dysuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
chromaturia	NNS	chromaturia	chromaturia	chromaturia	Y	B-AdverseReaction
.	.	.	.	.	N	O

POTIGA	NNP	potiga	potiga	potiga	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
gain	NN	gain	gain	gain	N	I-AdverseReaction
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
mean	JJ	mean	mean	mean	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
increasing	VBG	increasing	increasing	increas	N	I-AdverseReaction
by	IN	by	by	by	N	O
0.2	CD	0.2	0.2	0.2	N	O
kg	NNS	kg	kg	kg	N	O
,	,	,	,	,	N	O
1.2	CD	1.2	1.2	1.2	N	O
kg	NN	kg	kg	kg	N	O
,	,	,	,	,	N	O
1.6	CD	1.6	1.6	1.6	N	O
kg	NN	kg	kg	kg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
2.7	CD	2.7	2.7	2.7	N	O
kg	NN	kg	kg	kg	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
600	CD	600	600	600	N	O
mg	NNS	mg	mg	mg	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
,	,	,	,	,	N	O
900	CD	900	900	900	N	O
mg	NNS	mg	mg	mg	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
200	CD	200	200	200	N	O
mg	NNS	mg	mg	mg	N	O
per	IN	per	per	per	N	O
day	NN	day	day	day	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Additional	JJ	additional	additional	addit	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Observed	NNP	observed	observed	observ	N	O
during	IN	during	during	dure	N	O
All	NNP	all	all	all	N	O
Phase	NNP	phase	phase	phase	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O

Following	VBG	following	following	follow	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
list	NN	list	list	list	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
during	IN	during	during	dure	N	O
all	DT	all	all	all	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
:	:	:	:	:	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
nystagmus	RB	nystagmus	nystagmus	nystagmu	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
spasms	NNS	spasms	spasm	spasm	Y	I-AdverseReaction
,	,	,	,	,	N	O
alopecia	NN	alopecia	alopecia	alopecia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nephrolithiasis	NN	nephrolithiasis	nephrolithiasis	nephrolithiasi	Y	B-AdverseReaction
,	,	,	,	,	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
euphoric	JJ	euphoric	euphoric	euphor	Y	B-AdverseReaction
mood	NN	mood	mood	mood	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
colic	NN	colic	colic	colic	Y	I-AdverseReaction
,	,	,	,	,	N	O
coma	NN	coma	coma	coma	Y	B-AdverseReaction
,	,	,	,	,	N	O
encephalopathy	NN	encephalopathy	encephalopathy	encephalopathi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Comparison	NNP	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
Gender	NNP	gender	gender	gender	N	O
,	,	,	,	,	N	O
Age	NNP	age	age	age	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Race	NNP	race	race	race	N	O

The	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
profile	NN	profile	profile	profil	N	O
of	IN	of	of	of	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
for	IN	for	for	for	N	O
females	NNS	females	female	femal	N	O
and	CC	and	and	and	N	O
males	NNS	males	male	male	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
are	VBP	are	are	are	N	O
insufficient	JJ	insufficient	insufficient	insuffici	N	O
data	NNS	data	data	data	N	O
to	TO	to	to	to	N	O
support	VB	support	support	support	N	O
meaningful	JJ	meaningful	meaningful	meaning	N	O
analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
by	IN	by	by	by	N	O
age	NN	age	age	age	N	O
or	CC	or	or	or	N	O
race	NN	race	race	race	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
86%	CD	86%	86%	86%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
studied	VBD	studied	studied	studi	N	O
was	VBD	was	wa	wa	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
aged	VBN	aged	aged	age	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
or	CC	or	or	or	N	O
older	JJR	older	older	older	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RETINAL	JJ	retinal	retinal	retin	N	B-AdverseReaction
ABNORMALITIES	NNP	abnormalities	abnormality	abnorm	N	I-AdverseReaction
AND	NNP	and	and	and	N	O
POTENTIAL	NNP	potential	potential	potenti	N	B-Factor
VISION	NNP	vision	vision	vision	N	B-AdverseReaction
LOSS	NNP	loss	loss	loss	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
RETINAL	JJ	retinal	retinal	retin	N	B-AdverseReaction
ABNORMALITIES	NNP	abnormalities	abnormality	abnorm	N	I-AdverseReaction
AND	NNP	and	and	and	N	O
POTENTIAL	NNP	potential	potential	potenti	N	B-Factor
VISION	NNP	vision	vision	vision	N	B-AdverseReaction
LOSS	NNP	loss	loss	loss	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
with	IN	with	with	with	N	O
funduscopic	NN	funduscopic	funduscopic	funduscop	N	O
features	NNS	features	feature	featur	N	O
similar	JJ	similar	similar	similar	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
those	DT	those	those	those	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
retinal	JJ	retinal	retinal	retin	N	I-AdverseReaction
pigment	NN	pigment	pigment	pigment	N	I-AdverseReaction
dystrophies	NNS	dystrophies	dystrophy	dystrophi	N	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
damage	NN	damage	damage	damag	N	B-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
photoreceptors	NNS	photoreceptors	photoreceptors	photoreceptor	N	I-AdverseReaction
and	CC	and	and	and	N	O
vision	NN	vision	vision	vision	N	B-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
found	VBN	found	found	found	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
visual	JJ	visual	visual	visual	N	I-AdverseReaction
acuity	NN	acuity	acuity	acuiti	N	I-AdverseReaction
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	B-Factor
possible	JJ	possible	possible	possibl	N	I-Factor
to	TO	to	to	to	N	I-Factor
determine	VB	determine	determine	determin	N	I-Factor
whether	IN	whether	whether	whether	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
caused	VBD	caused	caused	caus	N	O
this	DT	this	this	thi	N	O
decreased	JJ	decreased	decreased	decreas	N	B-AdverseReaction
visual	JJ	visual	visual	visual	N	I-AdverseReaction
acuity	NN	acuity	acuity	acuiti	N	I-AdverseReaction
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
baseline	NN	baseline	baseline	baselin	N	O
assessments	NNS	assessments	assessment	assess	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
available	JJ	available	available	avail	N	O
for	IN	for	for	for	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
one	CD	one	one	one	N	O
third	NN	third	third	third	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
eye	NN	eye	eye	eye	N	O
examinations	NNS	examinations	examination	examin	N	O
performed	VBD	performed	performed	perform	N	O
after	IN	after	after	after	N	O
approximately	RB	approximately	approximately	approxim	N	O
4	CD	4	4	4	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
were	VBD	were	were	were	N	O
found	VBN	found	found	found	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
pigmentary	JJ	pigmentary	pigmentary	pigmentari	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
earlier	JJR	earlier	earlier	earlier	N	O
onset	NN	onset	onset	onset	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
ruled	VBN	ruled	ruled	rule	N	O
out	RP	out	out	out	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
possible	JJ	possible	possible	possibl	N	O
that	IN	that	that	that	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
were	VBD	were	were	were	N	O
present	JJ	present	present	present	N	O
earlier	RBR	earlier	earlier	earlier	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
progression	NN	progression	progression	progress	N	O
of	IN	of	of	of	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
and	CC	and	and	and	N	O
their	PRP$	their	their	their	N	O
reversibility	NN	reversibility	reversibility	revers	N	O
are	VBP	are	are	are	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

POTIGA	NNP	potiga	potiga	potiga	N	O
should	MD	should	should	should	N	O
only	RB	only	only	onli	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
responded	VBN	responded	responded	respond	N	O
inadequately	RB	inadequately	inadequately	inadequ	N	O
to	TO	to	to	to	N	O
several	JJ	several	several	sever	N	O
alternative	JJ	alternative	alternative	altern	N	O
treatments	NNS	treatments	treatment	treatment	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
whom	WP	whom	whom	whom	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
outweigh	VBP	outweigh	outweigh	outweigh	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	O
loss	NN	loss	loss	loss	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
fail	VBP	fail	fail	fail	N	O
to	TO	to	to	to	N	O
show	VB	show	show	show	N	O
substantial	JJ	substantial	substantial	substanti	N	O
clinical	JJ	clinical	clinical	clinic	N	O
benefit	NN	benefit	benefit	benefit	N	O
after	IN	after	after	after	N	O
adequate	JJ	adequate	adequate	adequ	N	O
titration	NN	titration	titration	titrat	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
from	IN	from	from	from	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
periodic	NN	periodic	periodic	period	N	O
(	(	(	(	(	N	O
every	DT	every	every	everi	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
)	)	)	)	)	N	O
systematic	JJ	systematic	systematic	systemat	N	O
visual	JJ	visual	visual	visual	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
by	IN	by	by	by	N	O
an	DT	an	an	an	N	O
ophthalmic	JJ	ophthalmic	ophthalmic	ophthalm	N	O
professional	NN	professional	professional	profession	N	O
.	.	.	.	.	N	O

Testing	VBG	testing	testing	test	N	O
should	MD	should	should	should	N	O
include	VB	include	include	includ	N	O
visual	JJ	visual	visual	visual	N	O
acuity	NN	acuity	acuity	acuiti	N	O
and	CC	and	and	and	N	O
dilated	VBD	dilated	dilated	dilat	N	O
fundus	NN	fundus	fundus	fundu	N	O
photography	NN	photography	photography	photographi	N	O
.	.	.	.	.	N	O

Additional	JJ	additional	additional	addit	N	O
testing	NN	testing	testing	test	N	O
may	MD	may	may	may	N	O
include	VB	include	include	includ	N	O
fluorescein	JJ	fluorescein	fluorescein	fluorescein	N	O
angiograms	NNS	angiograms	angiogram	angiogram	N	O
(	(	(	(	(	N	O
FA	NNP	fa	fa	fa	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
optical	JJ	optical	optical	optic	N	O
coherence	NN	coherence	coherence	coher	N	O
tomography	NN	tomography	tomography	tomographi	N	O
(	(	(	(	(	N	O
OCT	NNP	oct	oct	oct	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
perimetry	NN	perimetry	perimetry	perimetri	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
electroretinograms	NNS	electroretinograms	electroretinogram	electroretinogram	N	O
(	(	(	(	(	N	O
ERG	NNP	erg	erg	erg	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
retinal	JJ	retinal	retinal	retin	N	O
pigmentary	JJ	pigmentary	pigmentary	pigmentari	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
or	CC	or	or	or	N	O
vision	NN	vision	vision	vision	N	O
changes	NNS	changes	change	chang	N	O
are	VBP	are	are	are	N	O
detected	VBN	detected	detected	detect	N	O
,	,	,	,	,	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
unless	IN	unless	unless	unless	N	O
no	DT	no	no	no	N	O
other	JJ	other	other	other	N	O
suitable	JJ	suitable	suitable	suitabl	N	O
treatment	NN	treatment	treatment	treatment	N	O
options	NNS	options	option	option	N	O
are	VBP	are	are	are	N	O
available	JJ	available	available	avail	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
outweigh	VBP	outweigh	outweigh	outweigh	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	O
loss	NN	loss	loss	loss	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RETINAL	JJ	retinal	retinal	retin	N	B-AdverseReaction
ABNORMALITIES	NNP	abnormalities	abnormality	abnorm	N	I-AdverseReaction
AND	NNP	and	and	and	N	O
POTENTIAL	NNP	potential	potential	potenti	N	B-Factor
VISION	NNP	vision	vision	vision	N	B-AdverseReaction
LOSS	NNP	loss	loss	loss	N	I-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

POTIGA	NNP	potiga	potiga	potiga	N	O
can	MD	can	can	can	N	O
cause	VB	cause	cause	caus	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
with	IN	with	with	with	N	O
funduscopic	NN	funduscopic	funduscopic	funduscop	N	O
features	NNS	features	feature	featur	N	O
similar	JJ	similar	similar	similar	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
those	DT	those	those	those	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
retinal	JJ	retinal	retinal	retin	N	O
pigment	NN	pigment	pigment	pigment	N	I-AdverseReaction
dystrophies	NNS	dystrophies	dystrophy	dystrophi	N	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
damage	NN	damage	damage	damag	N	B-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
photoreceptors	NNS	photoreceptors	photoreceptors	photoreceptor	N	I-AdverseReaction
and	CC	and	and	and	N	O
vision	NN	vision	vision	vision	N	B-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	VB	\n	\n	\n	N	O
Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
retinal	JJ	retinal	retinal	retin	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
found	VBN	found	found	found	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
visual	JJ	visual	visual	visual	N	O
acuity	NN	acuity	acuity	acuiti	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	B-Factor
possible	JJ	possible	possible	possibl	N	I-Factor
to	TO	to	to	to	N	I-Factor
determine	VB	determine	determine	determin	N	I-Factor
whether	IN	whether	whether	whether	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
caused	VBD	caused	caused	caus	N	O
this	DT	this	this	thi	N	O
decreased	JJ	decreased	decreased	decreas	N	B-AdverseReaction
visual	JJ	visual	visual	visual	N	I-AdverseReaction
acuity	NN	acuity	acuity	acuiti	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
The	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
progression	NN	progression	progression	progress	N	O
of	IN	of	of	of	N	O
retinal	JJ	retinal	retinal	retin	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
and	CC	and	and	and	N	O
their	PRP$	their	their	their	N	O
reversibility	NN	reversibility	reversibility	revers	N	O
are	VBP	are	are	are	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
Patients	NNPS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
fail	VBP	fail	fail	fail	N	O
to	TO	to	to	to	N	O
show	VB	show	show	show	N	O
substantial	JJ	substantial	substantial	substanti	N	O
clinical	JJ	clinical	clinical	clinic	N	O
benefit	NN	benefit	benefit	benefit	N	O
after	IN	after	after	after	N	O
adequate	JJ	adequate	adequate	adequ	N	O
titration	NN	titration	titration	titrat	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
from	IN	from	from	from	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
periodic	NN	periodic	periodic	period	N	O
(	(	(	(	(	N	O
every	DT	every	every	everi	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
)	)	)	)	)	N	O
systematic	JJ	systematic	systematic	systemat	N	O
visual	JJ	visual	visual	visual	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
by	IN	by	by	by	N	O
an	DT	an	an	an	N	O
ophthalmic	JJ	ophthalmic	ophthalmic	ophthalm	N	O
professional	NN	professional	professional	profession	N	O
.	.	.	.	.	N	O

Testing	VBG	testing	testing	test	N	O
should	MD	should	should	should	N	O
include	VB	include	include	includ	N	O
visual	JJ	visual	visual	visual	N	O
acuity	NN	acuity	acuity	acuiti	N	O
and	CC	and	and	and	N	O
dilated	VBD	dilated	dilated	dilat	N	O
fundus	NN	fundus	fundus	fundu	N	O
photography	NN	photography	photography	photographi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
If	IN	if	if	if	N	O
retinal	JJ	retinal	retinal	retin	N	O
pigmentary	JJ	pigmentary	pigmentary	pigmentari	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
or	CC	or	or	or	N	O
vision	NN	vision	vision	vision	N	O
changes	NNS	changes	change	chang	N	O
are	VBP	are	are	are	N	O
detected	VBN	detected	detected	detect	N	O
,	,	,	,	,	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
unless	IN	unless	unless	unless	N	O
no	DT	no	no	no	N	O
other	JJ	other	other	other	N	O
suitable	JJ	suitable	suitable	suitabl	N	O
treatment	NN	treatment	treatment	treatment	N	O
options	NNS	options	option	option	N	O
are	VBP	are	are	are	N	O
available	JJ	available	available	avail	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
outweigh	VBP	outweigh	outweigh	outweigh	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	O
loss	NN	loss	loss	loss	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
:	:	:	:	:	N	O
Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
urologic	JJ	urologic	urologic	urolog	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

POTIGA	NNP	potiga	potiga	potiga	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
discoloration	NN	discoloration	discoloration	discolor	N	I-AdverseReaction
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
skin	JJ	skin	skin	skin	N	O
discoloration	NN	discoloration	discoloration	discolor	N	O
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	O
consideration	NN	consideration	consideration	consider	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
alternative	JJ	alternative	alternative	altern	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Neuropsychiatric	JJ	neuropsychiatric	neuropsychiatric	neuropsychiatr	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
confusional	JJ	confusional	confusional	confusion	N	O
state	NN	state	state	state	N	O
,	,	,	,	,	N	O
psychotic	JJ	psychotic	psychotic	psychot	Y	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hallucinations	NNS	hallucinations	hallucination	hallucin	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	O
and	CC	and	and	and	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

QT	JJ	qt	qt	qt	N	B-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
:	:	:	:	:	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
certain	JJ	certain	certain	certain	N	O
heart	NN	heart	heart	heart	N	O
conditions	NNS	conditions	condition	condit	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
behaviors	NNS	behaviors	behavior	behavior	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Retinal	JJ	retinal	retinal	retin	N	O

Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
and	CC	and	and	and	N	O
Potential	NNP	potential	potential	potenti	N	O
Vision	NNP	vision	vision	vision	N	O
Loss	NNP	loss	loss	loss	N	O

POTIGA	NNP	potiga	potiga	potiga	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
retina	NN	retina	retina	retina	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
have	VBP	have	have	have	N	O
funduscopic	VBN	funduscopic	funduscopic	funduscop	N	B-AdverseReaction
features	NNS	features	feature	featur	N	I-AdverseReaction
similar	JJ	similar	similar	similar	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
those	DT	those	those	those	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
retinal	JJ	retinal	retinal	retin	N	I-AdverseReaction
pigment	NN	pigment	pigment	pigment	N	I-AdverseReaction
dystrophies	NNS	dystrophies	dystrophy	dystrophi	N	I-AdverseReaction
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
damage	NN	damage	damage	damag	N	B-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
photoreceptors	NNS	photoreceptors	photoreceptors	photoreceptor	N	I-AdverseReaction
and	CC	and	and	and	N	O
vision	NN	vision	vision	vision	N	B-AdverseReaction
loss	NN	loss	loss	loss	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
originally	RB	originally	originally	origin	N	O
enrolled	VBN	enrolled	enrolled	enrol	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
and	CC	and	and	and	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
generally	RB	generally	generally	gener	N	O
taken	VBN	taken	taken	taken	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
long	JJ	long	long	long	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
time	NN	time	time	time	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
ongoing	JJ	ongoing	ongoing	ongo	N	O
extension	NN	extension	extension	extens	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
one	CD	one	one	one	N	O
third	NN	third	third	third	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
eye	NN	eye	eye	eye	N	O
examinations	NNS	examinations	examination	examin	N	O
performed	VBD	performed	performed	perform	N	O
after	IN	after	after	after	N	O
approximately	RB	approximately	approximately	approxim	N	O
4	CD	4	4	4	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
were	VBD	were	were	were	N	O
found	VBN	found	found	found	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
pigmentary	JJ	pigmentary	pigmentary	pigmentari	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
an	DT	an	an	an	N	O
earlier	JJR	earlier	earlier	earlier	N	O
onset	NN	onset	onset	onset	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
ruled	VBN	ruled	ruled	rule	N	O
out	RP	out	out	out	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
possible	JJ	possible	possible	possibl	N	O
that	IN	that	that	that	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
were	VBD	were	were	were	N	O
present	JJ	present	present	present	N	O
earlier	RBR	earlier	earlier	earlier	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
.	.	.	.	.	N	O

POTIGA	NNP	potiga	potiga	potiga	N	O
causes	VBZ	causes	cause	caus	N	O
skin	FW	skin	skin	skin	N	B-AdverseReaction
,	,	,	,	,	N	O
scleral	JJ	scleral	scleral	scleral	N	B-AdverseReaction
,	,	,	,	,	N	O
nail	JJ	nail	nail	nail	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mucous	JJ	mucous	mucous	mucou	N	B-AdverseReaction
membrane	NN	membrane	membrane	membran	N	I-AdverseReaction
discoloration	NN	discoloration	discoloration	discolor	N	I-AdverseReaction
and	CC	and	and	and	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
clear	JJ	clear	clear	clear	N	O
whether	IN	whether	whether	whether	N	O
this	DT	this	this	thi	N	O
discoloration	NN	discoloration	discoloration	discolor	N	B-AdverseReaction
is	VBZ	is	is	is	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
pigmentary	JJ	pigmentary	pigmentary	pigmentari	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
had	VBD	had	had	had	N	O
no	DT	no	no	no	N	B-Negation
such	JJ	such	such	such	N	O
discoloration	NN	discoloration	discoloration	discolor	N	B-AdverseReaction
.	.	.	.	.	N	O

Funduscopic	NNP	funduscopic	funduscopic	funduscop	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
have	VBP	have	have	have	N	O
most	VBN	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
been	VBN	been	been	been	N	O
described	VBN	described	described	describ	N	O
as	IN	as	a	as	N	O
perivascular	JJ	perivascular	perivascular	perivascular	N	B-AdverseReaction
pigmentation	NN	pigmentation	pigmentation	pigment	Y	I-AdverseReaction
(	(	(	(	(	N	O
bone	JJ	bone	bone	bone	N	I-AdverseReaction
spicule	NN	spicule	spicule	spicul	N	I-AdverseReaction
pattern	NN	pattern	pattern	pattern	N	I-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
retinal	JJ	retinal	retinal	retin	N	I-AdverseReaction
periphery	NN	periphery	periphery	peripheri	N	I-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
as	IN	as	a	as	N	O
areas	NNS	areas	area	area	N	O
of	IN	of	of	of	N	O
focal	JJ	focal	focal	focal	N	B-AdverseReaction
retinal	JJ	retinal	retinal	retin	N	I-AdverseReaction
pigment	NN	pigment	pigment	pigment	N	I-AdverseReaction
epithelium	NN	epithelium	epithelium	epithelium	N	I-AdverseReaction
clumping	NN	clumping	clumping	clump	N	I-AdverseReaction
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
found	VBN	found	found	found	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
visual	JJ	visual	visual	visual	N	I-AdverseReaction
acuity	NN	acuity	acuity	acuiti	N	I-AdverseReaction
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
assess	VB	assess	ass	assess	N	O
whether	IN	whether	whether	whether	N	B-Factor
POTIGA	NNP	potiga	potiga	potiga	N	O
caused	VBD	caused	caused	caus	N	O
their	PRP$	their	their	their	N	O
decreased	JJ	decreased	decreased	decreas	N	B-AdverseReaction
visual	JJ	visual	visual	visual	N	I-AdverseReaction
acuity	NN	acuity	acuity	acuiti	N	I-AdverseReaction
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
baseline	NN	baseline	baseline	baselin	N	O
assessments	NNS	assessments	assessment	assess	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
available	JJ	available	available	avail	N	O
for	IN	for	for	for	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
have	VBP	have	have	have	N	O
had	VBN	had	had	had	N	O
more	RBR	more	more	more	N	O
extensive	JJ	extensive	extensive	extens	N	O
diagnostic	JJ	diagnostic	diagnostic	diagnost	N	O
retinal	JJ	retinal	retinal	retin	N	O
evaluations	NNS	evaluations	evaluation	evalu	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
results	NNS	results	result	result	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
evaluations	NNS	evaluations	evaluation	evalu	N	O
were	VBD	were	were	were	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
dystrophy	NN	dystrophy	dystrophy	dystrophi	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
electroretinogram	NN	electroretinogram	electroretinogram	electroretinogram	Y	I-AdverseReaction
and	CC	and	and	and	N	O
electrooculogram	NN	electrooculogram	electrooculogram	electrooculogram	Y	I-AdverseReaction
of	IN	of	of	of	N	O
both	DT	both	both	both	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
fluorescein	NN	fluorescein	fluorescein	fluorescein	N	I-AdverseReaction
angiography	NN	angiography	angiography	angiographi	Y	I-AdverseReaction
and	CC	and	and	and	N	O
diminished	JJ	diminished	diminished	diminish	N	B-AdverseReaction
sensitivity	NN	sensitivity	sensitivity	sensit	N	I-AdverseReaction
on	IN	on	on	on	N	I-AdverseReaction
visual	JJ	visual	visual	visual	N	I-AdverseReaction
field	NN	field	field	field	N	I-AdverseReaction
testing	VBG	testing	testing	test	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
progression	NN	progression	progression	progress	N	O
of	IN	of	of	of	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
reversibility	NN	reversibility	reversibility	revers	N	O
after	IN	after	after	after	N	O
drug	NN	drug	drug	drug	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
are	VBP	are	are	are	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	B-Factor
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
ophthalmologic	JJ	ophthalmologic	ophthalmologic	ophthalmolog	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
should	MD	should	should	should	N	O
only	RB	only	only	onli	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
responded	VBN	responded	responded	respond	N	O
inadequately	RB	inadequately	inadequately	inadequ	N	O
to	TO	to	to	to	N	O
several	JJ	several	several	sever	N	O
alternative	JJ	alternative	alternative	altern	N	O
treatments	NNS	treatments	treatment	treatment	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
whom	WP	whom	whom	whom	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
outweigh	VBP	outweigh	outweigh	outweigh	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
retinal	JJ	retinal	retinal	retin	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
and	CC	and	and	and	N	O
potential	JJ	potential	potential	potenti	N	O
vision	NN	vision	vision	vision	N	O
loss	NN	loss	loss	loss	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
fail	VBP	fail	fail	fail	N	O
to	TO	to	to	to	N	O
show	VB	show	show	show	N	O
substantial	JJ	substantial	substantial	substanti	N	O
clinical	JJ	clinical	clinical	clinic	N	O
benefit	NN	benefit	benefit	benefit	N	O
after	IN	after	after	after	N	O
adequate	JJ	adequate	adequate	adequ	N	O
titration	NN	titration	titration	titrat	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
from	IN	from	from	from	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
baseline	NN	baseline	baseline	baselin	N	O
ophthalmologic	IN	ophthalmologic	ophthalmologic	ophthalmolog	N	O
testing	VBG	testing	testing	test	N	O
by	IN	by	by	by	N	O
an	DT	an	an	an	N	O
ophthalmic	JJ	ophthalmic	ophthalmic	ophthalm	N	O
professional	NN	professional	professional	profession	N	O
and	CC	and	and	and	N	O
follow	VB	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	RP	up	up	up	N	O
testing	VBG	testing	testing	test	N	O
every	DT	every	every	everi	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
best	JJS	best	best	best	N	O
method	NN	method	method	method	N	O
of	IN	of	of	of	N	O
detection	NN	detection	detection	detect	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
optimal	JJ	optimal	optimal	optim	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
periodic	JJ	periodic	periodic	period	N	O
ophthalmologic	JJ	ophthalmologic	ophthalmologic	ophthalmolog	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
are	VBP	are	are	are	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
cannot	VBP	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
should	MD	should	should	should	N	O
usually	RB	usually	usually	usual	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
ophthalmologic	JJ	ophthalmologic	ophthalmologic	ophthalmolog	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
program	NN	program	program	program	N	O
should	MD	should	should	should	N	O
include	VB	include	include	includ	N	O
visual	JJ	visual	visual	visual	N	O
acuity	NN	acuity	acuity	acuiti	N	O
testing	NN	testing	testing	test	N	O
and	CC	and	and	and	N	O
dilated	VBD	dilated	dilated	dilat	N	O
fundus	NN	fundus	fundus	fundu	N	O
photography	NN	photography	photography	photographi	N	O
.	.	.	.	.	N	O

Additional	JJ	additional	additional	addit	N	O
testing	NN	testing	testing	test	N	O
may	MD	may	may	may	N	O
include	VB	include	include	includ	N	O
fluorescein	JJ	fluorescein	fluorescein	fluorescein	N	O
angiograms	NNS	angiograms	angiogram	angiogram	N	O
(	(	(	(	(	N	O
FA	NNP	fa	fa	fa	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
optical	JJ	optical	optical	optic	N	O
coherence	NN	coherence	coherence	coher	N	O
tomography	NN	tomography	tomography	tomographi	N	O
(	(	(	(	(	N	O
OCT	NNP	oct	oct	oct	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
perimetry	NN	perimetry	perimetry	perimetri	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
electroretinograms	NNS	electroretinograms	electroretinogram	electroretinogram	N	O
(	(	(	(	(	N	O
ERG	NNP	erg	erg	erg	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
retinal	JJ	retinal	retinal	retin	N	O
pigmentary	JJ	pigmentary	pigmentary	pigmentari	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
or	CC	or	or	or	N	O
vision	NN	vision	vision	vision	N	O
changes	NNS	changes	change	chang	N	O
are	VBP	are	are	are	N	O
detected	VBN	detected	detected	detect	N	O
,	,	,	,	,	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
unless	IN	unless	unless	unless	N	O
no	DT	no	no	no	N	O
other	JJ	other	other	other	N	O
suitable	JJ	suitable	suitable	suitabl	N	O
treatment	NN	treatment	treatment	treatment	N	O
options	NNS	options	option	option	N	O
are	VBP	are	are	are	N	O
available	JJ	available	available	avail	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
outweigh	VBP	outweigh	outweigh	outweigh	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	O
loss	NN	loss	loss	loss	N	B-Factor
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Urinary	JJ	urinary	urinary	urinari	N	O
Retention	NN	retention	retention	retent	N	O

POTIGA	NNP	potiga	potiga	potiga	N	O
caused	VBD	caused	caused	caus	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
generally	RB	generally	generally	gener	N	O
reported	VBN	reported	reported	report	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
observed	VBN	observed	observed	observ	N	O
later	RB	later	later	later	N	O
.	.	.	.	.	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
in	IN	in	in	in	N	O
29	CD	29	29	29	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
365	CD	365	365	365	N	O
(	(	(	(	(	N	O
approximately	RB	approximately	approximately	approxim	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
epilepsy	JJ	epilepsy	epilepsy	epilepsi	Y	O
database	NN	database	database	databas	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
29	CD	29	29	29	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
17%	CD	17%	17%	17%	N	O
)	)	)	)	)	N	O
required	VBN	required	required	requir	N	O
catheterization	NN	catheterization	catheterization	catheter	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
voiding	NN	voiding	voiding	void	N	O
residuals	NNS	residuals	residual	residu	N	O
of	IN	of	of	of	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
500	CD	500	500	500	N	O
mL	NN	ml	ml	ml	N	O
.	.	.	.	.	N	O

POTIGA	NNP	potiga	potiga	potiga	N	O
was	VBD	was	wa	wa	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
5	CD	5	5	5	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
required	VBD	required	required	requir	N	O
catheterization	NN	catheterization	catheterization	catheter	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
all	DT	all	all	all	N	O
were	VBD	were	were	were	N	O
able	JJ	able	able	abl	N	O
to	TO	to	to	to	N	O
void	VB	void	void	void	N	O
spontaneously	RB	spontaneously	spontaneously	spontan	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
3	CD	3	3	3	N	O
patients	NNS	patients	patient	patient	N	O
continued	JJ	continued	continued	continu	N	O
intermittent	JJ	intermittent	intermittent	intermitt	N	O
self	NN	self	self	self	N	O
-	:	-	-	-	N	O
catheterization	NN	catheterization	catheterization	catheter	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
patients	NNS	patients	patient	patient	N	O
continued	VBD	continued	continued	continu	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
able	JJ	able	able	abl	N	O
to	TO	to	to	to	N	O
void	VB	void	void	void	N	O
spontaneously	RB	spontaneously	spontaneously	spontan	N	O
after	IN	after	after	after	N	O
catheter	NN	catheter	catheter	cathet	N	O
removal	NN	removal	removal	remov	N	O
.	.	.	.	.	N	O

Hydronephrosis	NN	hydronephrosis	hydronephrosis	hydronephrosi	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
had	VBD	had	had	had	N	O
associated	VBN	associated	associated	associ	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
that	WDT	that	that	that	N	O
resolved	VBD	resolved	resolved	resolv	N	O
upon	IN	upon	upon	upon	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
.	.	.	.	.	N	O

Hydronephrosis	NN	hydronephrosis	hydronephrosis	hydronephrosi	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	B-Negation
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
"	NNP	"	"	"	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
,	,	,	,	,	N	O
"	NNP	"	"	"	N	O
"	NNP	"	"	"	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
hesitation	NN	hesitation	hesitation	hesit	N	I-AdverseReaction
,	,	,	,	,	N	O
"	NNP	"	"	"	N	O
and	CC	and	and	and	N	O
"	NNP	"	"	"	N	O
dysuria	NNS	dysuria	dysuria	dysuria	Y	B-AdverseReaction
"	NN	"	"	"	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
,	,	,	,	,	N	O
2.2%	CD	2.2%	2.2%	2.2%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
,	,	,	,	,	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	B-Factor
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
urinary	JJ	urinary	urinary	urinari	N	O
retention	NN	retention	retention	retent	N	O
on	IN	on	on	on	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
,	,	,	,	,	N	O
urologic	JJ	urologic	urologic	urolog	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
monitored	VBN	monitored	monitored	monitor	N	O
.	.	.	.	.	N	O

Closer	NNP	closer	closer	closer	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
other	JJ	other	other	other	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
urinary	JJ	urinary	urinary	urinari	N	O
retention	NN	retention	retention	retent	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
benign	JJ	benign	benign	benign	N	O
prostatic	JJ	prostatic	prostatic	prostat	N	O
hyperplasia	NN	hyperplasia	hyperplasia	hyperplasia	Y	O
[	NNP	[	[	[	N	O
BPH	NNP	bph	bph	bph	Y	O
])	NNP	])	])	])	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
unable	JJ	unable	unable	unabl	N	O
to	TO	to	to	to	N	O
communicate	VB	communicate	communicate	commun	N	O
clinical	JJ	clinical	clinical	clinic	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
cognitively	RB	cognitively	cognitively	cognit	N	O
impaired	JJ	impaired	impaired	impair	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
use	VBP	use	use	use	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
affect	VB	affect	affect	affect	N	O
voiding	VBG	voiding	voiding	void	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
anticholinergics	NNS	anticholinergics	anticholinergic	anticholinerg	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
comprehensive	JJ	comprehensive	comprehensive	comprehens	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
urologic	JJ	urologic	urologic	urolog	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	B-Factor
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Skin	NNP	skin	skin	skin	N	O
Discoloration	NN	discoloration	discoloration	discolor	N	O

POTIGA	NNP	potiga	potiga	potiga	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
discoloration	NN	discoloration	discoloration	discolor	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
discoloration	NN	discoloration	discoloration	discolor	N	I-AdverseReaction
is	VBZ	is	is	is	N	O
generally	RB	generally	generally	gener	N	O
described	VBN	described	described	describ	N	O
as	IN	as	a	as	N	O
blue	JJ	blue	blue	blue	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
has	VBZ	has	ha	ha	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
described	VBN	described	described	describ	N	O
as	IN	as	a	as	N	O
grey	JJ	grey	grey	grey	N	O
-	:	-	-	-	N	O
blue	NN	blue	blue	blue	N	O
or	CC	or	or	or	N	O
brown	NN	brown	brown	brown	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
on	IN	on	on	on	N	O
or	CC	or	or	or	N	O
around	IN	around	around	around	N	O
the	DT	the	the	the	N	O
lips	NNS	lips	lip	lip	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
nail	JJ	nail	nail	nail	N	O
beds	NNS	beds	bed	bed	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
fingers	NNS	fingers	finger	finger	N	O
or	CC	or	or	or	N	O
toes	NNS	toes	toe	toe	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
more	JJR	more	more	more	N	O
widespread	JJ	widespread	widespread	widespread	N	O
involvement	NN	involvement	involvement	involv	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
face	NN	face	face	face	N	O
and	CC	and	and	and	N	O
legs	NN	legs	leg	leg	N	O
has	VBZ	has	ha	ha	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Discoloration	NN	discoloration	discoloration	discolor	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
palate	NN	palate	palate	palat	N	I-AdverseReaction
,	,	,	,	,	N	O
sclera	NN	sclera	sclera	sclera	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
conjunctiva	NN	conjunctiva	conjunctiva	conjunctiva	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
developed	VBD	developed	developed	develop	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
discoloration	NN	discoloration	discoloration	discolor	N	I-AdverseReaction
,	,	,	,	,	N	O
generally	RB	generally	generally	gener	N	O
after	IN	after	after	after	N	O
2	CD	2	2	2	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
higher	JJR	higher	higher	higher	N	O
doses	NNS	doses	dos	dose	N	O
(	(	(	(	(	N	O
900	CD	900	900	900	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
whom	WP	whom	whom	whom	N	O
the	DT	the	the	the	N	O
status	NN	status	status	statu	N	O
of	IN	of	of	of	N	O
both	DT	both	both	both	N	O
skin	FW	skin	skin	skin	N	B-AdverseReaction
,	,	,	,	,	N	O
nail	NN	nail	nail	nail	N	B-AdverseReaction
,	,	,	,	,	N	O
lip	NN	lip	lip	lip	N	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
mucous	JJ	mucous	mucous	mucou	N	B-AdverseReaction
membrane	NN	membrane	membrane	membran	N	I-AdverseReaction
discoloration	NN	discoloration	discoloration	discolor	N	I-AdverseReaction
and	CC	and	and	and	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
pigmentary	JJ	pigmentary	pigmentary	pigmentari	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
,	,	,	,	,	N	O
approximately	RB	approximately	approximately	approxim	N	O
a	DT	a	a	a	N	O
quarter	NN	quarter	quarter	quarter	N	O
of	IN	of	of	of	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
skin	NN	skin	skin	skin	N	B-AdverseReaction
,	,	,	,	,	N	O
nail	NN	nail	nail	nail	N	B-AdverseReaction
,	,	,	,	,	N	O
lip	NN	lip	lip	lip	N	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
mucous	JJ	mucous	mucous	mucou	N	B-AdverseReaction
membrane	NN	membrane	membrane	membran	N	I-AdverseReaction
discoloration	NN	discoloration	discoloration	discolor	N	I-AdverseReaction
had	VBD	had	had	had	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
pigmentary	JJ	pigmentary	pigmentary	pigmentari	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Information	NN	information	information	inform	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
consequences	NNS	consequences	consequence	consequ	N	O
,	,	,	,	,	N	O
reversibility	NN	reversibility	reversibility	revers	N	O
,	,	,	,	,	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pathophysiology	NN	pathophysiology	pathophysiology	pathophysiolog	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
skin	NN	skin	skin	skin	N	B-AdverseReaction
abnormalities	VBZ	abnormalities	abnormality	abnorm	N	I-AdverseReaction
remains	VBZ	remains	remains	remain	N	O
incomplete	JJ	incomplete	incomplete	incomplet	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
of	IN	of	of	of	N	O
more	RBR	more	more	more	N	O
extensive	JJ	extensive	extensive	extens	N	O
systemic	JJ	systemic	systemic	system	N	O
involvement	NN	involvement	involvement	involv	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
excluded	VBN	excluded	excluded	exclud	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
skin	JJ	skin	skin	skin	N	O
discoloration	NN	discoloration	discoloration	discolor	N	O
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	O
consideration	NN	consideration	consideration	consider	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
to	TO	to	to	to	N	O
changing	VBG	changing	changing	chang	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
alternate	JJ	alternate	alternate	altern	N	O
medication	NN	medication	medication	medic	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Neuropsychiatric	NNP	neuropsychiatric	neuropsychiatric	neuropsychiatr	N	O
Symptoms	NNP	symptoms	symptom	symptom	N	O

Confusional	JJ	confusional	confusional	confusion	N	B-AdverseReaction
state	NN	state	state	state	N	I-AdverseReaction
,	,	,	,	,	N	O
psychotic	JJ	psychotic	psychotic	psychot	Y	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hallucinations	NNS	hallucinations	hallucination	hallucin	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
as	IN	as	a	as	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
resulting	VBG	resulting	resulting	result	N	O
from	IN	from	from	from	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
more	JJR	more	more	more	N	O
common	JJ	common	common	common	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
group	NN	group	group	group	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
effects	NNS	effects	effect	effect	N	O
were	VBD	were	were	were	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
and	CC	and	and	and	N	O
generally	RB	generally	generally	gener	N	O
appeared	VBD	appeared	appeared	appear	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
8	CD	8	8	8	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Half	NN	half	half	half	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
hallucinations	NNS	hallucinations	hallucination	hallucin	Y	B-AdverseReaction
or	CC	or	or	or	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	B-AdverseReaction
required	VBN	required	required	requir	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
two	CD	two	two	two	N	O
-	:	-	-	-	N	O
thirds	NNS	thirds	third	third	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	B-AdverseReaction
in	IN	in	in	in	N	O
controlled	JJ	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
had	VBD	had	had	had	N	O
no	DT	no	no	no	N	O
prior	JJ	prior	prior	prior	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
history	NN	history	history	histori	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
vast	JJ	vast	vast	vast	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
trials	NNS	trials	trial	trial	N	O
resolved	VBD	resolved	resolved	resolv	N	O
within	IN	within	within	within	N	O
7	CD	7	7	7	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
.	.	.	.	.	N	O

Rapid	JJ	rapid	rapid	rapid	N	O
titration	NN	titration	titration	titrat	N	O
at	IN	at	at	at	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
doses	NNS	doses	dos	dose	N	O
appeared	VBD	appeared	appeared	appear	N	O
to	TO	to	to	to	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hallucinations	NNS	hallucinations	hallucination	hallucin	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Major	JJ	major	major	major	N	O
Neuropsychiatric	NNP	neuropsychiatric	neuropsychiatric	neuropsychiatr	N	B-AdverseReaction
Symptoms	NNP	symptoms	symptom	symptom	N	I-AdverseReaction
in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Epilepsy	NNP	epilepsy	epilepsy	epilepsi	Y	O
Trials	NNS	trials	trial	trial	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Number	NNP	number	number	number	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Number	NNP	number	number	number	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Discontinuing	VBG	discontinuing	discontinuing	discontinu	N	O

POTIGA	NNP	potiga	potiga	potiga	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
813	CD	813	813	813	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
427	CD	427	427	427	N	O
)	)	)	)	)	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
813	CD	813	813	813	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
427	CD	427	427	427	N	O
)	)	)	)	)	N	O

Confusional	NNP	confusional	confusional	confusion	N	B-AdverseReaction
state	NN	state	state	state	N	I-AdverseReaction
75	CD	75	75	75	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
32	CD	32	32	32	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Psychosis	NN	psychosis	psychosis	psychosi	Y	B-AdverseReaction
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Hallucinationsa	$	hallucinationsa	hallucinationsa	hallucinationsa	N	B-AdverseReaction
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

a	DT	a	a	a	N	O
Hallucinations	NNP	hallucinations	hallucination	hallucin	Y	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
visual	JJ	visual	visual	visual	N	B-AdverseReaction
,	,	,	,	,	N	O
auditory	JJ	auditory	auditory	auditori	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mixed	JJ	mixed	mixed	mix	N	B-AdverseReaction
hallucinations	NNS	hallucinations	hallucination	hallucin	Y	I-AdverseReaction
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	O
and	CC	and	and	and	N	O
Somnolence	NN	somnolence	somnolence	somnol	Y	O

POTIGA	NNP	potiga	potiga	potiga	N	O
causes	VBZ	causes	cause	caus	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
23%	CD	23%	23%	23%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
and	CC	and	and	and	N	O
9%	CD	9%	9%	9%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
22%	CD	22%	22%	22%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
and	CC	and	and	and	N	O
12%	CD	12%	12%	12%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
and	CC	and	and	and	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
;	:	;	;	;	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
and	CC	and	and	and	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
mild	JJ	mild	mild	mild	N	O
to	TO	to	to	to	N	O
moderate	VB	moderate	moderate	moder	N	O
in	IN	in	in	in	N	O
intensity	NN	intensity	intensity	intens	N	O
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
titration	NN	titration	titration	titrat	N	O
phase	NN	phase	phase	phase	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
continued	VBD	continued	continued	continu	N	O
on	IN	on	on	on	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
appeared	VBD	appeared	appeared	appear	N	O
to	TO	to	to	to	N	O
diminish	VB	diminish	diminish	diminish	N	O
with	IN	with	with	with	N	O
continued	JJ	continued	continued	continu	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
QT	NNP	qt	qt	qt	N	O
Interval	NNP	interval	interval	interv	N	O
Effect	NNP	effect	effect	effect	N	O

A	DT	a	a	a	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
conduction	NN	conduction	conduction	conduct	N	O
showed	VBD	showed	showed	show	N	O
that	IN	that	that	that	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
produced	VBD	produced	produced	produc	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
7.7	CD	7.7	7.7	7.7	N	B-Severity
-	:	-	-	-	N	I-Severity
msec	NN	msec	msec	msec	N	I-Severity
QT	NNP	qt	qt	qt	N	B-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
in	IN	in	in	in	N	O
healthy	JJ	healthy	healthy	healthi	N	O
volunteers	NNS	volunteers	volunteer	volunt	N	O
titrated	VBD	titrated	titrated	titrat	N	O
to	TO	to	to	to	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
3	CD	3	3	3	N	O
times	NNS	times	time	time	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
prolonging	VBG	prolonging	prolonging	prolong	N	I-AdverseReaction
effect	NN	effect	effect	effect	N	O
occurred	VBD	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
3	CD	3	3	3	N	O
hours	NNS	hours	hour	hour	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
when	WRB	when	when	when	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
is	VBZ	is	is	is	N	O
prescribed	VBN	prescribed	prescribed	prescrib	N	O
with	IN	with	with	with	N	O
medicines	NNS	medicines	medicine	medicin	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
increase	VB	increase	increase	increas	N	O
QT	NNP	qt	qt	qt	N	O
interval	JJ	interval	interval	interv	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
known	VBN	known	known	known	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
,	,	,	,	,	N	O
congestive	JJ	congestive	congestive	congest	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	O
hypertrophy	NN	hypertrophy	hypertrophy	hypertrophi	Y	O
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Suicidal	NNP	suicidal	suicidal	suicid	N	O
Behavior	NNP	behavior	behavior	behavior	N	O
and	CC	and	and	and	N	O
Ideation	NNP	ideation	ideation	ideat	N	O

Antiepileptic	JJ	antiepileptic	antiepileptic	antiepilept	N	O
drugs	NNS	drugs	drug	drug	N	O
(	(	(	(	(	N	O
AEDs	NNP	aeds	aeds	a	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
,	,	,	,	,	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
these	DT	these	these	these	N	O
drugs	NNS	drugs	drug	drug	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
indication	NN	indication	indication	indic	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
any	DT	any	any	ani	N	O
AED	NNP	aed	aed	a	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
indication	NN	indication	indication	indic	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
or	CC	or	or	or	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
,	,	,	,	,	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
unusual	JJ	unusual	unusual	unusu	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
mood	NN	mood	mood	mood	N	O
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	O
.	.	.	.	.	N	O

Pooled	JJ	pooled	pooled	pool	N	O
analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
199	CD	199	199	199	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
mono	SYM	mono	mono	mono	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
-	:	-	-	-	N	O
therapy	NN	therapy	therapy	therapi	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
11	CD	11	11	11	N	O
different	JJ	different	different	differ	N	O
AEDs	NNP	aeds	aeds	a	N	O
showed	VBD	showed	showed	show	N	O
that	IN	that	that	that	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
one	CD	one	one	one	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
AEDs	NNP	aeds	aeds	a	N	O
had	VBD	had	had	had	N	O
approximately	RB	approximately	approximately	approxim	N	O
twice	RB	twice	twice	twice	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
(	(	(	(	(	N	O
adjusted	VBN	adjusted	adjusted	adjust	N	O
relative	NN	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	O
1.8	CD	1.8	1.8	1.8	N	O
,	,	,	,	,	N	O
95%	CD	95%	95%	95%	N	O
confidence	NN	confidence	confidence	confid	N	O
interval	NN	interval	interval	interv	N	O
[	NNP	[	[	[	N	O
CI	NNP	ci	ci	ci	N	O
]	NN	]	]	]	N	O
:	:	:	:	:	N	O
1.2	CD	1.2	1.2	1.2	N	O
,	,	,	,	,	N	O
2.7	CD	2.7	2.7	2.7	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thinking	NN	thinking	thinking	think	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
treatment	NN	treatment	treatment	treatment	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
12	CD	12	12	12	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
estimated	VBN	estimated	estimated	estim	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
or	CC	or	or	or	N	O
ideation	NN	ideation	ideation	ideat	N	I-AdverseReaction
among	IN	among	among	among	N	O
27	CD	27	27	27	N	O
,	,	,	,	,	N	O
863	CD	863	863	863	N	O
AED	NNP	aed	aed	a	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
0.43%	CD	0.43%	0.43%	0.43%	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
0.24%	CD	0.24%	0.24%	0.24%	N	O
among	IN	among	among	among	N	O
16	CD	16	16	16	N	O
,	,	,	,	,	N	O
029	CD	029	029	029	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
representing	VBG	representing	representing	repres	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
of	IN	of	of	of	N	O
approximately	RB	approximately	approximately	approxim	N	O
1	CD	1	1	1	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thinking	NN	thinking	thinking	think	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
for	IN	for	for	for	N	O
every	DT	every	every	everi	N	O
530	CD	530	530	530	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
4	CD	4	4	4	N	O
suicides	NNS	suicides	suicide	suicid	N	B-AdverseReaction
in	IN	in	in	in	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	B-Factor
is	VBZ	is	is	is	N	I-Factor
too	RB	too	too	too	N	I-Factor
small	JJ	small	small	small	N	I-Factor
to	TO	to	to	to	N	O
allow	VB	allow	allow	allow	N	O
any	DT	any	any	ani	N	O
conclusion	NN	conclusion	conclusion	conclus	N	O
about	IN	about	about	about	N	O
drug	NN	drug	drug	drug	N	O
effect	NN	effect	effect	effect	N	O
on	IN	on	on	on	N	O
suicide	NN	suicide	suicide	suicid	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
with	IN	with	with	with	N	O
AEDs	NNP	aeds	aeds	a	N	B-DrugClass
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
as	RB	as	a	as	N	O
early	JJ	early	early	earli	N	O
as	IN	as	a	as	N	O
1	CD	1	1	1	N	O
week	NN	week	week	week	N	O
after	IN	after	after	after	N	O
starting	VBG	starting	starting	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
AEDs	NNP	aeds	aeds	a	N	O
and	CC	and	and	and	N	O
persisted	VBN	persisted	persisted	persist	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
assessed	VBN	assessed	assessed	assess	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
most	JJS	most	most	most	N	O
trials	NNS	trials	trial	trial	N	O
included	VBD	included	included	includ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
analysis	NN	analysis	analysis	analysi	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
extend	VB	extend	extend	extend	N	O
beyond	IN	beyond	beyond	beyond	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
or	CC	or	or	or	N	O
behavior	JJ	behavior	behavior	behavior	N	O
beyond	IN	beyond	beyond	beyond	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
could	MD	could	could	could	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
assessed	VBN	assessed	assessed	assess	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
generally	RB	generally	generally	gener	N	O
consistent	JJ	consistent	consistent	consist	N	O
among	IN	among	among	among	N	O
drugs	NNS	drugs	drug	drug	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
analyzed	VBD	analyzed	analyzed	analyz	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
finding	NN	finding	finding	find	N	O
of	IN	of	of	of	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
with	IN	with	with	with	N	O
AEDs	NNP	aeds	aeds	a	N	O
of	IN	of	of	of	N	O
varying	VBG	varying	varying	vari	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
and	CC	and	and	and	N	O
across	IN	across	across	across	N	O
a	DT	a	a	a	N	O
range	NN	range	range	rang	N	O
of	IN	of	of	of	N	O
indications	NNS	indications	indication	indic	N	O
suggests	VBZ	suggests	suggests	suggest	N	O
that	IN	that	that	that	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
applies	NNS	applies	applies	appli	N	O
to	TO	to	to	to	N	O
all	DT	all	all	all	N	O
AEDs	NNP	aeds	aeds	a	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
indication	NN	indication	indication	indic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
vary	JJ	vary	vary	vari	N	O
substantially	RB	substantially	substantially	substanti	N	O
by	IN	by	by	by	N	O
age	NN	age	age	age	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
to	TO	to	to	to	N	O
100	CD	100	100	100	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
analyzed	VBD	analyzed	analyzed	analyz	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
shows	NNS	shows	show	show	N	O
absolute	NN	absolute	absolute	absolut	N	O
and	CC	and	and	and	N	O
relative	JJ	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	O
by	IN	by	by	by	N	O
indication	NN	indication	indication	indic	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
evaluated	JJ	evaluated	evaluated	evalu	N	O
AEDs	NNP	aeds	aeds	a	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
Suicidal	NNP	suicidal	suicidal	suicid	N	B-AdverseReaction
Thoughts	NNP	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
Behaviors	NNS	behaviors	behavior	behavior	N	I-AdverseReaction
by	IN	by	by	by	N	O
Indication	NNP	indication	indication	indic	N	O
for	IN	for	for	for	N	O
Antiepileptic	NNP	antiepileptic	antiepileptic	antiepilept	N	O
Drugs	NNP	drugs	drug	drug	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Pooled	NNP	pooled	pooled	pool	N	O
Analysis	NN	analysis	analysis	analysi	N	O

Indication	NNP	indication	indication	indic	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Patients	NNPS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Events	NNS	events	event	event	N	O
per	IN	per	per	per	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
Patients	NNS	patients	patient	patient	N	O
Drug	JJ	drug	drug	drug	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Events	NNS	events	event	event	N	O
per	IN	per	per	per	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
Patients	NNS	patients	patient	patient	N	O
Relative	JJ	relative	relative	rel	N	O
Risk	NN	risk	risk	risk	N	O
:	:	:	:	:	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
Drug	NNP	drug	drug	drug	N	O
Patients	NNPS	patients	patient	patient	N	O
Incidence	NNP	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Patients	NNP	patients	patient	patient	N	O
Risk	NNP	risk	risk	risk	N	O
Difference	NNP	difference	difference	differ	N	O
:	:	:	:	:	N	O
Additional	JJ	additional	additional	addit	N	O
Drug	NN	drug	drug	drug	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Events	NNS	events	event	event	N	O
per	IN	per	per	per	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
Patients	NNS	patients	patient	patient	N	O

Epilepsy	NNP	epilepsy	epilepsy	epilepsi	Y	O
1.0	CD	1.0	1.0	1.0	N	O
3.4	CD	3.4	3.4	3.4	N	O
3.5	CD	3.5	3.5	3.5	N	O
2.4	CD	2.4	2.4	2.4	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
5.7	CD	5.7	5.7	5.7	N	O
8.5	CD	8.5	8.5	8.5	N	O
1.5	CD	1.5	1.5	1.5	N	O
2.9	CD	2.9	2.9	2.9	N	O

Other	JJ	other	other	other	N	O
1.0	CD	1.0	1.0	1.0	N	O
1.8	CD	1.8	1.8	1.8	N	O
1.9	CD	1.9	1.9	1.9	N	O
0.9	CD	0.9	0.9	0.9	N	O

Total	JJ	total	total	total	N	O
2.4	CD	2.4	2.4	2.4	N	O
4.3	CD	4.3	4.3	4.3	N	O
1.8	CD	1.8	1.8	1.8	N	O
1.9	CD	1.9	1.9	1.9	N	O

The	DT	the	the	the	N	O
relative	JJ	relative	relative	rel	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
thoughts	NNS	thoughts	thought	thought	N	I-AdverseReaction
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
the	DT	the	the	the	N	O
absolute	NN	absolute	absolute	absolut	N	O
risk	NN	risk	risk	risk	N	O
differences	NNS	differences	difference	differ	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
for	IN	for	for	for	N	O
epilepsy	NN	epilepsy	epilepsy	epilepsi	Y	O
and	CC	and	and	and	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
indications	NNS	indications	indication	indic	N	O
.	.	.	.	.	N	O

Anyone	NN	anyone	anyone	anyon	N	O

considering	VBG	considering	considering	consid	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
AED	NNP	aed	aed	a	N	O
must	MD	must	must	must	N	O
balance	VB	balance	balance	balanc	N	O
this	DT	this	this	thi	N	O
risk	NN	risk	risk	risk	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
untreated	JJ	untreated	untreated	untreat	N	O
illness	NN	illness	illness	ill	N	O
.	.	.	.	.	N	O

Epilepsy	NNP	epilepsy	epilepsy	epilepsi	Y	O
and	CC	and	and	and	N	O
many	JJ	many	many	mani	N	O
other	JJ	other	other	other	N	O
illnesses	NNS	illnesses	illness	ill	N	O
for	IN	for	for	for	N	O
which	WDT	which	which	which	N	O
AEDs	NNP	aeds	aeds	a	N	O
are	VBP	are	are	are	N	O
prescribed	VBN	prescribed	prescribed	prescrib	N	O
are	VBP	are	are	are	N	O
themselves	PRP	themselves	themselves	themselv	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
morbidity	NN	morbidity	morbidity	morbid	N	O
and	CC	and	and	and	N	O
mortality	NN	mortality	mortality	mortal	N	O
and	CC	and	and	and	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
and	CC	and	and	and	N	O
behavior	NN	behavior	behavior	behavior	N	O
.	.	.	.	.	N	O

Should	MD	should	should	should	N	O
suicidal	VB	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
and	CC	and	and	and	N	O
behavior	JJ	behavior	behavior	behavior	N	O
emerge	NN	emerge	emerge	emerg	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
prescriber	NN	prescriber	prescriber	prescrib	N	O
needs	VBZ	needs	need	need	N	O
to	TO	to	to	to	N	O
consider	VB	consider	consider	consid	N	O
whether	IN	whether	whether	whether	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
given	VBN	given	given	given	N	O
patient	NN	patient	patient	patient	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
illness	NN	illness	illness	ill	N	O
being	VBG	being	being	be	N	O
treated	VBN	treated	treated	treat	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
their	PRP$	their	their	their	N	O
caregivers	NNS	caregivers	caregiver	caregiv	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
families	NNS	families	family	famili	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
informed	VBN	informed	informed	inform	N	O
that	IN	that	that	that	N	O
AEDs	NNP	aeds	aeds	a	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
and	CC	and	and	and	N	O
behavior	NN	behavior	behavior	behavior	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
need	NN	need	need	need	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
alert	JJ	alert	alert	alert	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
or	CC	or	or	or	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
;	:	;	;	;	N	O
any	DT	any	any	ani	N	O
unusual	JJ	unusual	unusual	unusu	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
mood	NN	mood	mood	mood	N	O
or	CC	or	or	or	N	O
behavior	NN	behavior	behavior	behavior	N	O
;	:	;	;	;	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
of	IN	of	of	of	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	O
thoughts	NNS	thoughts	thought	thought	N	O
,	,	,	,	,	N	O
behavior	NN	behavior	behavior	behavior	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
thoughts	NNS	thoughts	thought	thought	N	O
about	IN	about	about	about	N	O
self	PRP	self	self	self	N	O
-	:	-	-	-	N	O
harm	NN	harm	harm	harm	N	O
.	.	.	.	.	N	O

Behaviors	NNS	behaviors	behavior	behavior	N	O
of	IN	of	of	of	N	O
concern	NN	concern	concern	concern	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
reported	VBN	reported	reported	report	N	O
immediately	RB	immediately	immediately	immedi	N	O
to	TO	to	to	to	N	O
healthcare	VB	healthcare	healthcare	healthcar	N	O
providers	NNS	providers	provider	provid	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Withdrawal	NNP	withdrawal	withdrawal	withdraw	N	O
Seizures	NNS	seizures	seizure	seizur	Y	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
AEDs	NNP	aeds	aeds	a	N	O
,	,	,	,	,	N	O
when	WRB	when	when	when	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
is	VBZ	is	is	is	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
withdrawn	VBN	withdrawn	withdrawn	withdrawn	Y	O
gradually	RB	gradually	gradually	gradual	N	O
when	WRB	when	when	when	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
minimize	VB	minimize	minimize	minim	N	O
the	DT	the	the	the	N	O
potential	NN	potential	potential	potenti	N	O
of	IN	of	of	of	N	O
increased	JJ	increased	increased	increas	N	O
seizure	NN	seizure	seizure	seizur	Y	O
frequency	NN	frequency	frequency	frequenc	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
dosage	NN	dosage	dosage	dosag	N	O
of	IN	of	of	of	N	O
POTIGA	NNP	potiga	potiga	potiga	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
reduced	VBN	reduced	reduced	reduc	N	O
over	IN	over	over	over	N	O
a	DT	a	a	a	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
unless	IN	unless	unless	unless	N	O
safety	NN	safety	safety	safeti	N	O
concerns	NNS	concerns	concern	concern	N	O
require	VBP	require	require	requir	N	O
abrupt	JJ	abrupt	abrupt	abrupt	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
.	.	.	.	.	N	O

